At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,393 enrolled
Drug / intervention
adefovir dipivoxildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-marketing Surveillance to Monitor the Safety of HEPSERA(Adefovir Dipivoxil 10mg) Adminstered in Korean Subjects According to the Prescribing Information
In Brief
An observational study evaluating adefovir dipivoxil for Hepatitis B. Completed, enrolled 4,393 participants.
Detailed Summary
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of adefovir dipivoxil administered in Korean CHB patients according to the prescribing information
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2004
Primary CompletionFeb 2010
First PostedApr 2011
TodayJul 2026
First PostedApr 5, 2011
Enrollment StartAug 1, 2004
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.2 years ago
Interventions
adefovir dipivoxildrug
Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.